Drugs / inactivated polio vaccine
inactivated polio vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02643368 Comparator | Dec 2015 → Feb 2016 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inactivated polio vaccine | “Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age” NCT02643368 ↗ |
| Known as | inactivated poliovirus vaccine | “Monovalent Type 2 Oral Poliovirus Vaccine (mOPV2) and inactivated poliovirus vaccine (IPV) are used to respond to type 2 poliovirus outbreaks.” PMID 29571817 ↗ Mar 2018 |
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02643368 ↗ |
| Modality | Vaccine | “inactivated poliovirus vaccine” NCT02643368 ↗ |
| Route | Intramuscular | “IPV (0·5 mL of type 1 [Mahoney, 40 D-antigen units], type 2 [MEF-1, 8 D-antigen units], and type 3 [Saukett, 32 D-antigen units]) administered intramuscularly with the first mOPV2 dose.” PMID 29571817 ↗ Mar 2018 |